Alembic gets USFDA nod for Oseltamivir Phosphate for Oral Suspension

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Oseltamivir Phosphate for Oral Suspension, 6 mg/mL.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Tamiflu Oral Suspension, 6 mg/mL, of Hoffmann-La Roche. Oseltamivir Phosphate is an influenza neuraminidase inhibitor (NAI) indicated for:

i) treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours, and

ii) Prophylaxis of influenza A and B in patients 1 year and older.

Oseltamivir Phosphate for Oral Suspension, 6 mg/mL, have an estimated market size of $ 27 million for twelve months ending March 2026 according to IQVIA.

Alembic has a cumulative total of 243 ANDA approvals (223 final approvals and 20 tentative approvals) from USFDA.

The post Alembic gets USFDA nod for Oseltamivir Phosphate for Oral Suspension appeared first on Express Pharma.